Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Monopar Therapeutics changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 16 | 12 | −4 |
| Shares | 395.3K | 418.2K | +22.8K (+5.8%) |
| Value | $268.1K | $310.1K | +$42.0K (+15.7%) |
New holders (1)
Institutions that held Monopar Therapeutics at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Securities, LLC | 47,058 | $34.4K | 0.00% |
Sold out (5)
Institutions that held Monopar Therapeutics at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| HRT Financial LP | 32,113 | $21.0K |
| FMR LLC | 5,500 | $3.75K |
| UBS Group AG | 2,568 | $1.75K |
| Morgan Stanley | 800 | $545 |
| Royal Bank of Canada | 100 | $0 |